Drug Profile
AMG 780
Alternative Names: AMG-780Latest Information Update: 15 Jan 2019
Price :
$50
*
At a glance
- Originator Amgen
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Angiopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 08 Jan 2019 Shire has been acquired and merged into Takeda
- 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in USA (IV, Infusion)
- 22 Jan 2016 Dyax has been acquired by and merged into Shire